Hitoki Nanaura

Dr. Hitoki Nanaura

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
HNHitoki Nanaura
Hitoki Nanaura
HKHonoka Kawamukai
Honoka Kawamukai
AFAyano Fujiwara
Ayano Fujiwara
TUTakeru Uehara
Takeru Uehara
YAYuichiro Aiba
Yuichiro Aiba
EMEiichiro Mori
Eiichiro Mori
Nuclear import receptors (NIRs) not only transport RNA-binding proteins (RBPs) but also modify phase transitions of RBPs by recognizing nuclear localization signals (NLSs). Toxic arginine-rich poly-dipeptides from C9orf72 interact with NIRs and cause nucleocytoplasmic transport deficit. However, the molecular basis for the toxicity of arginine-rich poly-dipeptides toward NIRs function as phase modifiers of RBPs remains unidentified. Here we show that arginine-rich poly-dipeptides impede the ability of NIRs to modify phase transitions of RBPs. Isothermal titration calorimetry and size-exclusion chromatography revealed that proline:arginine (PR) poly-dipeptides tightly bind karyopherin-β2 (Kapβ2) at 1:1 ratio. The nuclear magnetic resonances of Kapβ2 perturbed by PR poly-dipeptides partially overlapped with those perturbed by the designed NLS peptide, suggesting that PR poly-dipeptides target the NLS binding site of Kapβ2. The findings offer mechanistic insights into how phase transitions of RBPs are disabled in C9orf72-related neurodegeneration.

26 October 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
KIKeiko Imamura
Keiko Imamura
YIYuishin Izumi
Yuishin Izumi
NENaohiro Egawa
Naohiro Egawa
TATakashi Ayaki
Takashi Ayaki
MNMakiko Nagai
Makiko Nagai
HIHaruhisa Inoue
Haruhisa Inoue
Introduction Amyotrophic lateral sclerosis (ALS) is a progressive, severe neurodegenerative disease caused by motor neuron death. Development of a medicine for ALS is urgently needed, and induced pluripotent cell-based drug repurposing identified a Src/c-Abl inhibitor, bosutinib, as a candidate for molecular targeted therapy of ALS. A phase 1 study confirmed the safety and tolerability of bosutinib in a 12-week treatment of ALS patients. The objectives of this study are to evaluate the efficacy and longer-term safety of bosutinib in ALS patients. Methods and analysis An open-label, multicentre phase 2 study was designed. The study consisted of a 12-week observation period, a 1-week transitional period, a 24-week study treatment period and a 4-week follow-up period. Following the transitional period, patients whose total Revised ALS Functional Rating Scale (ALSFRS-R) score declined by 1 to 4 points during the 12-week observation period were to receive bosutinib for 24 weeks. In this study, 25 ALS patients will be enrolled; patients will be randomly assigned to the following groups: 12 patients in the 200 mg quaque die (QD) group and 13 patients in the 300 mg QD group of bosutinib. The safety and exploratory efficacy of bosutinib in ALS patients for 24 weeks will be assessed. Efficacy using the ALSFRS-R score will be compared with the external published data from an edaravone study (MCI186-19) and registry data from a multicentre ALS cohort study, the Japanese Consortium for Amyotrophic Lateral Sclerosis Research. Ethics and dissemination This study was approved by the ethics committees of Kyoto University, Tokushima University, Kitasato University, Tottori University, Nara Medical University School of Medicine, Toho University and Hiroshima University. The findings will be disseminated in peer-reviewed journals and at scientific conferences. Trial Registration number jRCT2051220002; Pre-results, NCT04744532; Pre-results

1 September 2020 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SISoichiro S. Ito
Soichiro S. Ito
YNYosuke Nakagawa
Yosuke Nakagawa
MMMasaya Matsubayashi
Masaya Matsubayashi
YSYoshihiko M. Sakaguchi
Yoshihiko M. Sakaguchi
SKShinko Kobashigawa
Shinko Kobashigawa
TKTadaaki Kirita
Tadaaki Kirita
The anticancer agent 5-fluorouracil (5-FU) is cytotoxic and often used to treat various cancers. 5-FU is thought to inhibit the enzyme thymidylate synthase, which plays a role in nucleotide synthesis and has been found to induce single- and double-strand DNA breaks. ATR Ser/Thr kinase (ATR) is a principal kinase in the DNA damage response and is activated in response to UV- and chemotherapeutic drug–induced DNA replication stress, but its role in cellular responses to 5-FU is unclear. In this study, we examined the effect of ATR inhibition on 5-FU sensitivity of mammalian cells. Using immunoblotting, we found that 5-FU treatment dose-dependently induced the phosphorylation of ATR at the autophosphorylation site Thr-1989 and thereby activated its kinase. Administration of 5-FU with a specific ATR inhibitor (ATRi) remarkably decreased cell survival, compared with 5-FU treatment combined with other major DNA repair kinases inhibitors. Of note, the ATR inhibition enhanced induction of DNA double-strand breaks and apoptosis in 5-FU–treated cells. Using gene expression analysis, we found that 5-FU induced the activation of the intra-S cell cycle checkpoint. Cells lacking the BRCA2 were sensitive to 5-FU in the presence of ATRi. Moreover, the ATR inhibition enhanced the efficacy of the 5-FU treatment, independently of the non-homologous end-joining and homologous recombination repair pathways. These findings suggest that ATR could be a potential therapeutic target in 5-FU–based chemotherapy.

1 November 2020 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SOShota Ozawa
Shota Ozawa
MMMasaya Matsubayashi
Masaya Matsubayashi
HNHitoki Nanaura
Hitoki Nanaura
MYMotoko Yanagita
Motoko Yanagita
KMKiyoshi Mori
Kiyoshi Mori
TNTakahiko Nakagawa
Takahiko Nakagawa
Podocyte injury is a critical step toward the progression of renal disease and is often associated with a loss of slit diaphragm (SD) proteins, including Podocin. While there is a possibility that the extracellular domain of these SD proteins can be a target for a pathological proteolysis, the precise mechanism driving the phenomenon remains unknown. Here we show that Matriptase, a membrane-anchored protein, was activated at podocytes in CKD patients and mice, while Matriptase inhibitors slowed the progression of mouse kidney disease. The mechanism could be accounted for by an imbalance favoring Matriptase over its cognate inhibitor, hepatocyte growth factor activator inhibitor type 1 (HAI-1), as conditional depletion of HAI-1 in podocytes accelerated podocyte injury in mouse model. Matriptase was capable of cleaving Podocin, but such a reaction was blocked by either HAI-1 or dominant negative Matriptase. Furthermore, the N-terminal of Podocin (Podocin-N), as a consequence of Matriptase cleavage of Podocin, translocated to nucleoli, suggesting that Podocin-N might be involved in the process of podocyte injury. Given these observations, we propose that the proteolytic cleavage of Podocin by Matriptase could potentially cause podocyte injury, and that targeting Matriptase could be a novel therapeutic strategy for CKD patients.

4 November 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
NENobuyuki Eura
Nobuyuki Eura
TMTakeshi K. Matsui
Takeshi K. Matsui
JLJoachim Luginbühl
Joachim Luginbühl
MMMasaya Matsubayashi
Masaya Matsubayashi
HNHitoki Nanaura
Hitoki Nanaura
EMEiichiro Mori
Eiichiro Mori
Summary: The brainstem controls heartbeat, blood pressure and respiration, which are life-sustaining functions, therefore, disorders of the brainstem can be lethal. Brain organoids derived from human pluripotent stem cells recapitulate the course of human brain development and are expected to be useful for medical research on central nervous system disorders. However, existing organoid models have limitations, hampering the elucidation of diseases affecting specific components of the brain. Here, we developed a method to generate human brainstem organoids (hBSOs), containing neural crest stem cells as well as midbrain/hindbrain progenitors, noradrenergic and cholinergic neurons, and dopaminergic neurons, demonstrated by specific electrophysiological signatures. Single-cell RNA sequence analysis, together with proteomics and electrophysiology, revealed that the cellular population in these organoids was similar to that of the human brainstem and neural crest, which raises the possibility of making use of hBSOs in grafting for transplantation, efficient drug screenings and modeling the neural crest diseases.

21 October 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
HNHitoki Nanaura
Hitoki Nanaura
HKHonoka Kawamukai
Honoka Kawamukai
AFAyano Fujiwara
Ayano Fujiwara
TUTakeru Uehara
Takeru Uehara
MNMari Nakanishi
Mari Nakanishi
EMEiichiro Mori
Eiichiro Mori
Low-complexity (LC) domains of proteins are found in about one fifth of human proteome, and a group of LC-domains form labile cross-β polymers and liquid-like droplets. Polymers and droplets formed from LC-domains are dynamically regulated by posttranslational modifications and molecular chaperones including nuclear transport receptors. Repeat expansion in the first intron of a gene designated C9orf72 , which is the most prevalent form of familial amyotrophic lateral sclerosis (ALS), causes nucleocytoplasmic transport deficit, however, the detailed mechanism remains unsolved. Here we show that the proline:arginine (PR) poly-dipeptides encoded by the C9orf72 repeat expansion bound nuclear transport receptor Kapβ2 through its nuclear localization signal (NLS) recognition motif, and inhibited the ability of Kapβ2 to melt fused in sarcoma (FUS) droplets by competing interaction with FUS. The findings in this study offer mechanistic insights as to how the C9orf72 repeat expansion disables nucleocytoplasmic transport and causes neurodegenerative diseases.